Skip to main content

Alumis

Alumis Inc is a clinical-stage biopharmaceutical enterprise headquartered in South San Francisco, California. The company focuses on the discovery, development, and commercialization of oral precision medicines designed to address severe autoimmune and inflammatory diseases. Its proprietary research and clinical pipeline targets specific molecular pathways to deliver targeted therapies for conditions such as plaque psoriasis and systemic lupus erythematosus. Principal revenue is currently earned through private capital financing arrangements, research grants, and development partnerships as the enterprise advances its clinical drug candidates. Alumis Inc is publicly listed on the Nasdaq Stock Market.

6 of the funds FundTelligence covers report a position in Alumis.

Legal name
Alumis Inc
Sector
Health Care
Country
United States
Funds holding it
6
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding Alumis

Loading...